Positive Topline Results Announced from Ph 1 Portion of Ph 1/2a Trial of IMM-1-104 in RAS-Mutant Solid Tumors March 26, 2024
Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline March 18, 2024
Domain Therapeutics and Chime Biologics announce manufacturing agreement to advance novel anti-CCR8 antibody for cancer immunotherapy March 18, 2024
Biotheus Expanded Partnership with Hansoh Pharma for Developing EGFR/cMET Bispecific ADCs March 18, 2024
Debio0123 Monotherapy trial expanded In Gynecological Cancers And Other Biomarker-Driven Solid Tumors March 12, 2024
Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Ph 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4 announced March 12, 2024
Vudalimab monotherapy generally well tolerated with encouraging clinical benefit for heavily-pretreated patients with high-risk metastatic CRPC March 5, 2024
Encouraging Safety & Efficacy Data in Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in metastatic CRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors Announced March 5, 2024
Enhertu granted Priority Review in the US for patients with metastatic HER2-positive solid tumours February 26, 2024
First Patient Dosed in Ph 1/2 Trial of TAC101-CLDN18.2 for the Treatment of Claudin 18.2+ Solid Tumors February 26, 2024
Ph 2 Portion of ALKOVE-1 Trial for Patients with ALK+ve NSCLC and other Solid Tumors initiated February 26, 2024
AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology and Immunology February 26, 2024
IND Applications approved by the U.S. FDA and China CDE for the First EpCAM CAR-T Targeted at Advanced Solid Tumors February 26, 2024
Erasca Announces Two Clinical Trial Collaboration & Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 & SEACRAFT-2 Trials February 26, 2024
ProfoundBio Raises $112 Million in Oversubscribed Series B Equity Financing to Advance its Clinical-Stage ADC Pipeline February 26, 2024
Medigene announces indication selection for the clinical development of its TCR-T therapy program in solid tumors February 26, 2024
Numab Therapeutics and Ono Pharmaceutical Announce an Option and Collaboration Agreement to Develop Multi-specific Antibody NM49 for Treatment of Cancer February 26, 2024
Jazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire Global Rights to KRAS Inhibitor Program February 26, 2024
FDA Accepts for Priority Review Supplemental NDA for Augtyro™ (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors February 26, 2024
